Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice

BACKGROUND: Fatigue was reported as the most common any-grade adverse event (18.3%), and the most common grade 3 or higher immune-related adverse event (irAE) (0.89%) in patients receiving PD-1/PD-L1 checkpoint inhibitors in clinical trial. METHODS: The aim of this retrospective multicenter study wa...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Transl Med
Main Authors: Cortellini, Alessio, Vitale, Maria G., De Galitiis, Federica, Di Pietro, Francesca R., Berardi, Rossana, Torniai, Mariangela, De Tursi, Michele, Grassadonia, Antonino, Di Marino, Pietro, Santini, Daniele, Zeppola, Tea, Anesi, Cecilia, Gelibter, Alain, Occhipinti, Mario Alberto, Botticelli, Andrea, Marchetti, Paolo, Rastelli, Francesca, Pergolesi, Federica, Tudini, Marianna, Silva, Rosa Rita, Mallardo, Domenico, Vanella, Vito, Ficorella, Corrado, Porzio, Giampiero, Ascierto, Paolo A.
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2019
Fag:
Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6857130/
https://ncbi.nlm.nih.gov/pubmed/31730009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-019-02132-x
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker